Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.
Researchers sought to determine whether adding anti-CD19 CAR-T cells to ibrutinib would improve remission rates in CLL.
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Researchers sought to determine the landscape of BTK inhibitors for treating patients with CLL.
Researchers sought to determine whether IgM levels would impact treatment responsiveness to ibrutinib in patients with CLL.
Researchers sought to identify novel therapeutic approaches to patients who develop Richter transformation.